Form 4: Phibro Animal Health CEO Sells Shares

Phibro Animal Health's President and CEO, Jack Bendheim, reported the sale of 10,560 Class A Common Stock shares through a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), reported the sale of Class A Common Stock.
• The sales were conducted by BFI Co., LLC, over which Mr. Bendheim exercises voting and dispositive power.
• A total of 10,560 shares were sold across three separate transactions between October 28, 2025, and October 30, 2025.
• On October 28, 2025, 3,520 shares were sold at a weighted average price of $41.5561, with prices ranging from $41.21 to $41.935.
• On October 29, 2025, 3,520 shares were sold at a weighted average price of $41.6554, with prices ranging from $41.33 to $41.94.
• On October 30, 2025, 3,520 shares were sold at a weighted average price of $41.0745, with prices ranging from $40.71 to $41.30.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following these transactions, BFI Co., LLC beneficially owns 44,440 shares, and Jack Bendheim directly owns 16,840 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be perceived negatively, the fact that it's part of a pre-arranged 10b5-1 plan mitigates some of the negative implications, suggesting a planned liquidity event rather than a reaction to adverse company news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The sales were conducted by BFI Co., LLC, over which Jack Bendheim, a director and officer, exercises voting and dispositive power. Mr. Bendheim disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The reduction in insider ownership, even if planned, might be viewed with slight caution, though the overall impact on the company's operations or strategy is minimal.

Key Dates

Recommendation

This Form 4 filing reports routine insider selling under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial planning and do not usually signal a change in the company's fundamental outlook or performance. Therefore, it does not warrant a change in investment thesis based solely on this filing.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Selling, Form 4, 10b5-1 Plan, Stock Sale, Director, CEO, 10% Owner